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Tyrosine kinase inhibitors have been widely used to probe the role of tyrosine phosphorylation in cellular signalling. These inhibitors exhibit an 
apparent specificity for tyrosine kinases over the serineithreonine kinases but little is known about their effects on other enzymes or biological 
systems. We demonstrate that genistein, erbstatin and a-cyanocinnamamides (tyrphostins) have inhibitory effects on fatty acid synthesis, lactate 
transport, mitochondrial oxidative phosphorylation and aldehyde dehydrogenase. We propose, therefore, that results obtained using tyrosine kinase 
inhibitors should be interpreted with caution, particularly if used at concentrations ufficient o inhibit these non-protein kinase-dependent events. 
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1. INTRODUCTION 
Protein phosphorylation on serine, threonine and ty- 
rosine residues is central to the regulation of a wide 
range of cellular processes including metabolism, the 
cell cycle, gene transcription/translation, and signal 
transduction by growth factor receptors and several on- 
cogene products. Over 100 protein kinases have been 
characterized and cloned [1,2], but determination of 
their role in cellular processes has often remained elu- 
sive. This has encouraged the development of low mo- 
lecular weight inhibitors, some of which appear to ex- 
hibit reasonable specificity for individual protein ki- 
nases despite their apparent similarity within the kinase 
core structure [3,4]. 
Inhibitors of protein kinases have been developed 
that interact at the ATP or peptide substrate binding 
site, or at domains involved in allosteric regulation (re- 
viewed in [4]). Erbstatin and genistein are examples of 
inhibitors that are competitive with substrate and ATP 
respectively, and which inhibit EGF receptor auto- 
phosphorylation more effectively than the CAMP-de- 
pendent protein kinase [5,6]. It might be predicted that 
inhibitors directed at the substrate binding site wouid 
be more specific than those acting at the ATP binding 
site. A series of such compounds with common hydroxy 
cis-cinnamamonitrile backbone structures, have been 
investigated intensively and have been termed tyr- 
phostins by Yaish et al. [7] (see also ref. [8], e.g. inhib- 
itors RG50864, ST271 and ST638 of Table I). These 
inhibitors exhibit both competitive and non-competitive 
inhibitory kinetics with the peptide substrate and, in 
most cases, are considerably more potent against the 
EGF receptor than the insulin receptor or serine/thre- 
onine-specific protein kinases [7-IO]. Indeed it has been 
reported that some tyrphostins can discriminate be- 
tween tyrosine kinases such as the EGF receptor and 
c-evbB2, which share considerable amino acid sequence 
homology [l 11. Furthermore, the potency of several ty- 
rosine kinase inhibitors (e.g. ST271 and t-Boc tyrosine 
aminomalonate) against the insulin receptor have been 
reported to be generally rather low (K, > 0.5 mM; 
[7,12]). 
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This degree of selectivity suggests that such com- 
pounds could serve as useful indicators of the involve- 
ment of tyrosine phosphorylation in specific cellular 
processes. For example tyrosine kinase inhibitors have 
anti-proliferative effects when added to EGF-stimu- 
iated cells in culture [I 1,131, block long-term potentia- 
tion in hippocampal slices [I43 and inhibit the lipogenic 
efects of insulin without apparent effects on the anti- 
lipolytic actions of the hormone [12]. 
Abbreviations: HEPES, 4-(2-hydroxyethyl)-l-piperazineethanesul- 
phonic acid; MOPS, morpholinopropane sulphomc acid; EGF, ep- 
idermal growth factor; PDGF, platelet-derived growth factor; TMPD, 
~,~,~,‘~-tetramethyl-~-phenyiene-diamine~ FCCP, carbonyt cya- 
nide ~-(t~fluoromethoxy)phenyl h drazone. 
The demonstration that tyrosine phosphorylation is 
involved in these highly complex biological processes is 
implicitly dependent on the specificity of the inhibitors 
for tyrosine kinases over other cellular processes. Ai- 
though genistein can inhibit &galactosidase [15] and 
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topoisomerases I and II [16], there is little information 
about the effects of the tyrosine kinase inhibitors (or 
other protein kinase inhibitors in general) on other cel- 
lular processes. 
During our preliminary studies on erbstatin, genistein 
and the tyrphostins RG50864, ST271 and ST638 on 
insulin signalling pathways it became apparent that 
these inhibitors exhibited a series of effects on cells 
which could not be explained by protein kinase inhibi- 
tion. Initially we found that some of the compounds 
inhibited basal rates of fatty acid synthesis in isolated 
fat cells. As the tyrphostins are structurally related to 
a-cyano-4-hydroxycinnamate and its derivatives, which 
are potent inhibitors of mitochondrial pyruvate trans- 
port (and as a consequence fatty acid synthesis; [ 17,l S]), 
plasma membrane H+-lactate co-transporters [171, and 
aldehyde dehydrogenase [ 191 we thus investigated the 
effects of these inhibitors on pyruvate/lactate transport, 
and aldehyde dehydrogenase. During the course of this 
work some of the inhibitors were also found to inhibit 
mitochondrial oxidative phosphorylation. 
2. MATERIALS AND METHODS 
2.1. Materials 
The tyrphostin inhibitors RG50864 [20](also coded 47 in ref. [21]), 
ST271 (coded 8 in ref. [22]) and ST638 (coded 13 in ref. [22]) were 
synthesized as described. Erbstatin was prepared according to the 
procedure of Anderson et al. [23]. Genistein was purchased from Apin 
Chemicals. All inhibitors were judged pure by spectral and thin-layer 
chromatography criteria and were dissolved in Me,SO; in all experi- 
ments appropriate controls with Me,SO were performed. 
2.2. Assays of fatty acid synthesis in isolated fat cells 
This was performed essentially as described by Rutter and Denton 
[24]. Isolated rat epididymal fat cells (- 0.1 g dry weight) were incubated 
at 37°C in 1 ml buffer (140 mM NaCI, 4.7 mM KCl, 1.25 mM CaC&. 
1.25 mM MgSO,, 2.4 mM NaH2P0,, 10 mM HEPES, 15 mM 
NaHCO,, 1 mM glucose, 1% (w/v) BSA, pH 7.4) containing 0.1-0.5 
PCi r+J-‘4C]glucose and msulin as required. Incubations were contin- 
ued for 30 min and radioactivity associated with triacylglycerol fatty 
acids and glycerol determined [25]. 
2.3. Measurement of oxygen consumption by isolated liver mitochon- 
dria 
Liver mitochondria were prepared from Wistar rats (250 g) as de- 
scribed [26]. Rates of oxygen uptake by mitochondria (approx. 1 mg 
protein/ml) were measured using a Clark-type oxygen electrode at 
37°C in 1 ml buffer containing 125 mM KCI, 10 mM MOPS, 5.5 mM 
Tris, 2.5 mM MgCl,, 2.5 mM potassium phosphate and 0.5 mM 
EGTA pH 7.2. Uncoupling activity of compounds was assessed by 
measuring their stimulation of oxygen uptake in the presence of 5 mM 
L-glutamate and 1 mM o-malate but no ADP. Respiratory chain 
inhibition was assayed in the presence of 1 mM ADP and substrates 
(5 mM pyruvate/l mM malate or 5 mM glutamate/l mM malate or 
5 mM Tris-succinate/l &ml rotenone or 10 mM ascorbate/0.3 mM 
TMPD). 
2.4. Measurement of lactate transport 
Assay of the specific monocarboxylate transporter in rat erythro- 
cytes was performed using a centrifuge stop technique [27]. In these 
experiments initial rates of uptake of 0.5 mM [U-‘4C]-L-lactate were 
measured over 15 s at 7°C. Inhibitors were preincubated with the cell 
suspension (10% haematocrit) for 2 min prior to measurement of 
transport. 
2.5 Assay of aldehyde dehydrogenase activity 
The low K,,, rat liver mitochondrial aldehyde dehydrogenase was 
purified by a-cyanocmnamate affinity chromatography [19]. The en- 
zyme was assayed spectrophotometrically at 30°C by following the 
production of NADH as A3, in buffer containing 100 mM NaCl, 20 
mM MOPS, 0.5 mM EDTA, pH 7.4, and the substrates acetaldehyde 
(0.1 mM) and NAD’ (0.5 mM). Inhibitors were present only during 
the period of the assay. Most of the inhibitors had considerable ab- 
sorbance at 340 nm restricting their use to concentrations less than 100 
PM. 
3. RESULTS AND DISCUSSION 
3.1. Effects of tyrosine kinase inhibitors on fatty acid 
synthesis 
The inhibitors RG50864 and ST271 were examined 
for their effects on fatty acid synthesis from D-[U- 
“C]glucose in isolated fat cells. The inhibitors had pro- 
nounced effects on both basal and insulin-stimulated 
fatty acid synthesis, but neither inhibitor caused any 
significant reduction in the magnitude of the insulin 
effect of on this process (approx. 3- to 4-fold in the 
presence or absence of 400 PM inhibitor; see Fig. 1). 
The mechanism underlying the effects of the inhib- 
itors on fatty acid synthesis is not known. The tyr- 
phostins are structurally related to a-cyano4-hy- 
droxycinnamate and its derivatives which inhibit mito- 
chondrial pyruvate transport and, as a consequence, 
fatty acid synthesis [17.18]. If the inhibitory effects of 
the tyrphostins on fatty acid synthesis were due to a 
similar mechanism an increase in lactate and pyruvate 
output into the medium might be expected. However, 
this does not appear to be the case since we observed 
no significant increase in extracellular lactate and py- 
ruvate concentrations (results not shown). Further- 
more, we observed no significant change in glyceride 
glycerol synthesis (results not shown) which also implies 
that the site of action of the inhibitors on fatty acid 
synthesis may be beyond the point of action of a-cyano- 
cinnamate (i.e. post-mitochondrial pyruvate transport). 
Interestingly, genistein has been reported to inhibit 
insulin-stimulated glucose oxidation without effect on 
insulin receptor autophosphorylation in isolated fat 
cells 281. In that study the basal rates of glucose oxida- 
tion were too low to conclude whether or not basal rates 
were similarly affected. Genistein is an analogue of 
phloretin and quercetin, well characterised and potent 
inhibitors of glucose transport [29,30]. It remains to be 
established whether this effect on glucose oxidation 
might be explained by a direct inhibition of the glucose 
transporter, rather than through inhibition of other in- 
sulin-stimulated protein serine/threonine kinases as sug- 
gested by Abler et al. [28]. 
The structural similarity between the tyrphostins and 
a-cyanocinnamate, and the results shown in Fig. 1, 
279 
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Fig. 1. Effects of tyrosine kinase inhibitors on glucose incorporation mto fat in rsolated fat cells. Isolated epididymal fat cells were incubated with 
n-fU-‘4C]glucose and the indicated concentrations of inhibitor RG50844 (circles) or ST271 (squares) in the absence (open symbols) or presence 
(filled symbols) of insulin. The data points represent means of two dete~inations. Quantitatively similar results were obtained in two further 
ex~riments where the effects of insulin were 4- to 7-fold. Experimental details are given in section 2. 
prompted us to perform a more detailed examination of 
systems which are affected by a-cyanocinnamates. 
These included pyruvate transport and respiratory 
chain activity of isolated mitochondria, plasma mem- 
brane H+-lactate co-transport, and aldehyde dehydro- 
genase. 
3.2. Effects of tyrosine kinase inhibitors on mitochon- 
dream pyruvate transport and respiratory chain activ- 
ity 
Mitochondrial pyruvate transport was measured in- 
directly by determining rates of pyruvate oxidation in 
isolated mitochondria. While inhibitor RG50864 had 
no significant effect, ST271, ST638 and genistein were 
inhibitors of pyruvate oxidation (200 ,uM inhibitor gave 
approx. 67%, 83% and 60% inhibition of oxygen up- 
take, respectively). In order to investigate the nature of 
this inhibition we carried out further experiments with 
isolated mitochondria. As shown in Table I, four of the 
inhibitors were found to be uncouplers of oxidative 
phospho~lation. Indeed, the compounds achieved ap- 
prox. 90% of the maximal extent of uncoupling ob- 
served with FCCP. Similar properties have been re- 
ported previously for SF6847 (as ST271 but with a ni- 
trile group in place of the amide) although the EC,, was 
significantly lower (10 nM) [31]. This is, perhaps, not 
surprising in view of the weak acid nature of the pheno- 
lit hydroxyl and the electron withdrawing nature of the 
nitrile group. At higher concentrations, however, the 
compounds were found to be respiratory chain inhib- 
itors; in the presence of 1 mM ADP and glutamate/ 
malate as oxidative substrates, we found that ST271, 
ST638 and genistein (all at 200pM) exhibited 60%, 85% 
and 58% inhibition of oxygen uptake, respectively. Sim- 
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ilarly, when succinate was used as a respiratory sub- 
strate, inhibitors ST271, ST638 and genistein (at 200 
FM) caused approx. 62%, 50% and 37% inhibition of 
oxygen uptake, respectively. No inhibition of ascorbate/ 
TMPD oxidation was observed with any of the inhib- 
itors. Thus the inhibitors have complex effects on mito- 
chondrial respiratory chain activity. Depending on the 
conditions used they can both uncouple oxidative phos- 
phorylation as well as act as respiratory chain inhibitors 
at complex III although a further site of action at com- 
plex I cannot be ruled out. Interestingly, we also found 
that staurosporine, a potent but non-specific inhibitor 
of protein kinases at nanomolar concentrations [32], 
also inhibited the respiratory chain; 1 ,uM staurosporine 
gave approx. 80% inhibition of glutamate/malate oxida- 
tion. 
3.3. Effects of tyrosine kinase inhibitors on H’-lactate 
co-transport and aldehyde dehydrogenase 
The effects of the inhibitors on He-lactate co-trans- 
port into isolated erythrocytes was examined at a phys- 
iological lactate concentration. This process involves a 
transporter which has similar properties to the pyruvate 
transporter of the inner mitochondrial membrane and, 
indeed, transporters with similar properties are present 
in almost all mammalian cells [33]. The most potent 
inhibitor was ST271 with an EC,, value in the micromo- 
lar range (Table I). By contrast, ST638 was the most 
potent inhibitor of aldehyde dehydrogenase with ST271 
having little detectable ffect up to 100 PM (Table I). 
Erbstatin had no apparent effects on the respiratory 
chain or aldehyde dehydrogenase, but it did have a 
weak inhibitory effect on lactate transport (Table I). 
However, after periods of storage as a solution at 4”C, 
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presumably as a result of decomposition to an unchar- 
acterized derivative, erbstatin became a relatively po- 
tent inhibitor (ECSo approx. 18 PM) of glutamate/ma- 
late oxidation by isolated mitchondia. In contrast genis- 
tein, a widely used tyrosine kinase inhibitor which is 
reported to be competitive with respect o ATP [5], had 
multiple inhibitory effects on respiratory chain activity, 
lactate transport and aldehyde dehydrogenase (Table I). 
4.4. General conclusions 
It is clear from these studies that the tyrosine kinase 
inhibitors used have multiple effects on protein kinase- 
independent events (lactate transport, respiratory chain 
activity and aldehyde dehydrogenase). Inhibition of 
fatty acid synthesis could, perhaps, be explained by the 
inhibition of protein-serine/threonine kinases involved 
in the regulation of acetyl-CoA carboxylase and/or py- 
ruvate dehydrogenase, the two key regulatory steps in 
this pathway, although we cannot rule out an effect of 
the inhibitors on cellular ATP levels. 
These apparently non-specific effects of the tyrosine 
kinase inhibitors is of some concern. Tyrosine kinase 
inhibitors have been used in several situations to infer 
the involvement of tyrosine kinase-dependent sig- 
nalling. For example, genistein, at a concentration of 
100 ,uM, has been reported to block long term potentia- 
tion in the hippocampus [14] and CD40/Bp50 B-cell 
receptor signalling [34]; this is a concentration which is 
significantly above the ECso value for inhibition of lac- 
tate transport (8.5 PM; Table I). Similarly, Hill et al. 
[35] have reported that 100 PM genistein inhibits 
PDGF-stimulated DNA synthesis in mouse fibroblasts. 
Furthermore, 100 PM ST638 and 80 ,uM RG50864 have 
been shown to inhibit the growth of A431 and HER14 
cells, respectively [9,13,20]. The behaviour of these tyro- 
sine kinase inhibitors could be explained through their 
ability to inhibit lactate transport, rather than via inhi- 
bition of a tyrosine kinase, particularly in the case of 
genistein and ST271. For example, many cultured cell 
lines possess few mitochondria and rely heavily on gly- 
colysis and thus an inhibition of H’-linked eftlux of the 
lactate produced could result in intracellular acidifica- 
tion, inhibition of glycolysis and a consequent drop in 
cellular ATP levels. Indeed, another inhibitor of lactate 
Inhibitor name 
RG50864 
Mitochonrial 
uncouplings 
50.0 f 0.9 
Lactatetransportb Aldehyde 
dehydrogenasebJ 
126*7/ 19.8 f 1.1 
27.6 f 1.8 7.2 f 1.d > 1ooc 
Uf3)2a 
0 
ST63 8 58.1 f 7.6 46.6 f 9.2e 6.0 f 0.8 
(0.50 l 0.06) 
OH 
Erbstatin N.E. 132 f 34c N.E. 
(0.60 l 0.10) 
Volume 316, number 3 FEBS LETTERS February 1993 
transport, quercetin (also a tyrosine kinase inhibitor) 
[36], causes cytoplasmic acidification and inhibition of 
glycolysis in Ehrlich ascites cells [37]. 
Inhibition of aldehyde dehydrogenases could also 
have important effects in certain experimental systems. 
Most notably, these enzymes are involved in the synthe- 
sis of the neurotransmitter y-aminobutyric acid [38]. 
and in the metabolism of aldehydes derived from hista- 
mine and dopamine [39]. Whether the concentrations of 
the inhibitors could reach levels high enough to uncou- 
ple or inhibit the respiratory chain in intact cells is not 
known, although genistein has been reported to have no 
significant effect on ATP levels in isolated fat cells [28]. 
However, importantly, little is known about the rates of 
uptake of these compounds into cells, whether they be- 
come accumulated within the cell, how rapidly they are 
metabolised and, finally, whether the intermediary or 
end products of their metabolism have effects on other 
cellular processes not described in the present study. 
Thus an interaction of these inhibitors with the respira- 
tory chain cannot be ruled out when they are added at 
extracellular concentrations approaching 100 PM. 
Whilst some of the effects of the compounds might be 
predicted based on their structural similarity to known 
inhibitors of lactate/pyruvate transport and aldehyde 
dehydrogenase, many of the effects we have observed 
were unexpected. This was particularly the case with 
genistein which clearly has effects on ATP-independent 
processes. Thus it remains quite possible that these com- 
pounds could inhibit cellular processes other than those 
described in the present study, which might also be 
important in signal transduction events and cellular me- 
tabolism. 
In conclusion, results derived from the use of tyrosine 
kinase inhibitors should be interpreted with great cau- 
tion until more is known about their effects on other 
non-protein kinase-dependent events. The involvement 
of a tyrosine kinase in a cellular process/signalling path- 
way cannot be concluded from the use of tyrosine ki- 
nase inhibitors alone until such knowledge is more com- 
plete. 
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